{"transactions":[{"id":1127509,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T20:07:03.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025."}],"balance_after":88000,"derivative":{"exercise_price":0.87,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001628280-25-028822","document":"wk-form4_1748894817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025028822/wk-form4_1748894817.xml","form_type":"4"}},{"id":1501838,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-24T20:13:50.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024."}],"balance_after":65000,"derivative":{"exercise_price":2.25,"expiration_date":"2034-05-23","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001628280-24-025206","document":"wk-form4_1716581610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024025206/wk-form4_1716581610.xml","form_type":"4"}},{"id":1851952,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:07:21.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023."}],"balance_after":21000,"derivative":{"exercise_price":1.37,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001628280-23-022455","document":"wf-form4_168694602658326.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023022455/wf-form4_168694602658326.xml","form_type":"4"}},{"id":1851951,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T20:07:21.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023."}],"balance_after":36918,"source":{"system":"sec-edgar","filing":"0001628280-23-022455","document":"wf-form4_168694602658326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023022455/wf-form4_168694602658326.xml","form_type":"4"}},{"id":2253245,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-27T20:18:08.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) May 26, 2023 and (ii) the Issuer's next annual meeting of stockholders following May 26, 2022."}],"balance_after":20000,"derivative":{"exercise_price":5.51,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-015589","document":"wf-form4_165368265462041.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022015589/wf-form4_165368265462041.xml","form_type":"4"}},{"id":2409981,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-07T16:14:32.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":12375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022."}],"balance_after":12375,"derivative":{"exercise_price":10.4,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":12375},"source":{"system":"sec-edgar","filing":"0001104659-22-012796","document":"tm225605-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465922012796/tm225605-12_4seq1.xml","form_type":"4"}},{"id":2409980,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-07T16:14:32.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer."}],"balance_after":6442,"source":{"system":"sec-edgar","filing":"0001104659-22-012796","document":"tm225605-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465922012796/tm225605-12_4seq1.xml","form_type":"4"}},{"id":2691098,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T20:17:38.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":12376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021."}],"balance_after":31768,"source":{"system":"sec-edgar","filing":"0001628280-21-011357","document":"wf-form4_162223302655299.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828021011357/wf-form4_162223302655299.xml","form_type":"4"}},{"id":2785878,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:58:52.000Z","date":"2021-03-16","kind":"other","acquired":true,"shares":2717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Distribution of shares by Domain Associates, LLC pro rata to its members."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Distribution of shares by Domain Associates, LLC pro rata to its members."}],"balance_after":3692,"source":{"system":"sec-edgar","filing":"0000904454-21-000348","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000348/edgar.xml","form_type":"4"}},{"id":2785877,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:58:52.000Z","date":"2021-03-16","kind":"other","acquired":false,"shares":11612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Associates, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Distribution of shares by Domain Associates, LLC pro rata to its members."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Distribution of shares by Domain Associates, LLC pro rata to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-21-000348","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000348/edgar.xml","form_type":"4"}},{"id":2785876,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:58:52.000Z","date":"2021-03-16","kind":"other","acquired":false,"shares":6192,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VI, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Distribution of shares by One Palmer Square Associates VI, L.P. pro rata to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-21-000348","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000348/edgar.xml","form_type":"4"}},{"id":2785875,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:58:52.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":4250,"price":15.87,"value":67447.5,"ownership":{"direct":false,"nature":"By DP VI Associates, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.61 to $16.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-21-000348","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000348/edgar.xml","form_type":"4"}},{"id":2785874,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:58:52.000Z","date":"2021-03-12","kind":"other","acquired":true,"shares":6192,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VI, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Partners VI, L.P. pro rata to its partners."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Partners VI, L.P. pro rata to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":6192,"source":{"system":"sec-edgar","filing":"0000904454-21-000348","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000348/edgar.xml","form_type":"4"}},{"id":2785873,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-16T16:58:52.000Z","date":"2021-03-12","kind":"other","acquired":false,"shares":619221,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Partners VI, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Partners VI, L.P. pro rata to its partners."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Partners VI, L.P. pro rata to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P., and of Domain Associates, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-21-000348","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000348/edgar.xml","form_type":"4"}},{"id":2901946,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-20T16:39:21.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests monthly over 12 months beginning on January 31, 2021."}],"balance_after":16500,"derivative":{"exercise_price":12.6,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0000904454-21-000034","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445421000034/edgar.xml","form_type":"4"}},{"id":2989542,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-06T10:04:46.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500."},{"field":"shares","element":"transactionShares","label":"F1","text":"On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests monthly over 12 months beginning on January 31, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On September 22, 2020 the Issuer effected a 1 for 4 reverse stock split, pursuant to which the exercise price was adjusted to $8.28 and the number of shares underlying the stock option was adjusted to 37,500."}],"balance_after":150000,"derivative":{"exercise_price":2.07,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000904454-20-000703","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445420000703/edgar.xml","form_type":"4/A","original_submission_date":"2020-01-10"}},{"id":3130531,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:38:31.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":6106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020."}],"balance_after":19392,"source":{"system":"sec-edgar","filing":"0001179110-20-006715","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911020006715/edgar.xml","form_type":"4"}},{"id":3299122,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299121,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299120,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299119,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2026-01-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299118,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":13.24,"expiration_date":"2024-12-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299117,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2023-12-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299116,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":8.64,"expiration_date":"2022-12-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299115,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.59,"expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299114,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2020-12-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299113,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":25159,"price":6.3,"value":158501.7,"ownership":{"direct":false,"nature":"By DP VIII Associates, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the merger agreement (the \"Merger Agreement\") among Achillion Pharmaceuticals, Inc. (\"Achillion\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc.  In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right (\"CVR\") per share.  Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299112,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":3393382,"price":6.3,"value":21378306.6,"ownership":{"direct":false,"nature":"By Domain Partners VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the merger agreement (the \"Merger Agreement\") among Achillion Pharmaceuticals, Inc. (\"Achillion\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc.  In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right (\"CVR\") per share.  Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3299111,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-29T17:30:21.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":36431,"price":6.3,"value":229515.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the merger agreement (the \"Merger Agreement\") among Achillion Pharmaceuticals, Inc. (\"Achillion\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc.  In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right (\"CVR\") per share.  Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-20-000088","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445420000088/edgar.xml","form_type":"4"}},{"id":3313196,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-10T16:48:07.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests monthly over 12 months beginning on January 31, 2020."}],"balance_after":100000,"derivative":{"exercise_price":2.07,"expiration_date":"2030-01-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000904454-20-000030","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445420000030/edgar.xml","form_type":"4"}},{"id":3443877,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":155584,"kind":"person","name":"DOMAIN PARTERS VII L P","position":1,"cik":"0001374150","reported_name":"DOMAIN PARTERS VII L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2019-08-08T16:23:15.000Z","date":"2019-08-06","kind":"purchase","acquired":true,"shares":187500,"price":4,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":187500,"derivative":{"exercise_price":4.4,"exercise_date":"2019-08-06","expiration_date":"2024-08-06","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000904454-19-000600","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445419000600/edgar.xml","form_type":"4"}},{"id":3443876,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":155584,"kind":"person","name":"DOMAIN PARTERS VII L P","position":1,"cik":"0001374150","reported_name":"DOMAIN PARTERS VII L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-08-08T16:23:15.000Z","date":"2019-08-06","kind":"purchase","acquired":true,"shares":250000,"price":4,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased as Units, each Unit consisting of one share of Common Stock and a Warrant to purchase 0.75 of one share of Common Stock, at a purchase price of $4.00 per Unit."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported ownership reflects the one-for-ten reverse split of the Common Stock effected on July 24, 2019."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"As managing members of One Palmer Square Associates VII, LLC, which is also the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 4,957 shares of Common Stock held by DP VII Associates, L.P."}],"balance_after":813433,"source":{"system":"sec-edgar","filing":"0000904454-19-000600","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445419000600/edgar.xml","form_type":"4"}},{"id":3506334,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T22:09:33.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":4967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, which vest in full on the earlier of (i) May 29, 2020 or (ii) the Issuer's next annual meeting of stockholders following May 29, 2019."}],"balance_after":13286,"source":{"system":"sec-edgar","filing":"0000904454-19-000452","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000452/edgar.xml","form_type":"4"}},{"id":3582898,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T13:02:35.000Z","date":"2019-03-21","kind":"other","acquired":true,"shares":1356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members."}],"balance_after":8319,"source":{"system":"sec-edgar","filing":"0000904454-19-000335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000335/edgar.xml","form_type":"4"}},{"id":3582897,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T13:02:35.000Z","date":"2019-03-21","kind":"other","acquired":false,"shares":17790,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VII, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Distribution of shares by One Palmer Square Associates VII, LLC pro rata to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-19-000335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000335/edgar.xml","form_type":"4"}},{"id":3582896,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T13:02:35.000Z","date":"2019-03-19","kind":"sale","acquired":false,"shares":1700,"price":45.25,"value":76925.0,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.16 to $45.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-19-000335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000335/edgar.xml","form_type":"4"}},{"id":3582895,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T13:02:35.000Z","date":"2019-03-19","kind":"sale","acquired":false,"shares":13629,"price":44.66,"value":608671.14,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.16 to $45.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":1700,"source":{"system":"sec-edgar","filing":"0000904454-19-000335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000335/edgar.xml","form_type":"4"}},{"id":3582894,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T13:02:35.000Z","date":"2019-03-19","kind":"other","acquired":true,"shares":17790,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VII, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Partners VII, L.P. pro rata to its partners."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Partners VII, L.P. pro rata to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":17790,"source":{"system":"sec-edgar","filing":"0000904454-19-000335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000335/edgar.xml","form_type":"4"}},{"id":3582893,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-21T13:02:35.000Z","date":"2019-03-19","kind":"other","acquired":false,"shares":1101080,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Partners VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Partners VII, L.P. pro rata to its partners."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Partners VII, L.P. pro rata to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-19-000335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445419000335/edgar.xml","form_type":"4"}},{"id":3626309,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-28T17:21:08.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 5,833 shares immediately, and as to the remaining 29, 167 shares monthly over 10 months, beginning on 03/01/2019."}],"balance_after":35000,"derivative":{"exercise_price":3.96,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000904454-19-000270","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445419000270/edgar.xml","form_type":"4"}},{"id":3686959,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-25T16:30:47.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal quarterly installments over the one-year period following the date of grant."}],"balance_after":42000,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000904454-19-000086","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445419000086/edgar.xml","form_type":"4"}},{"id":3833141,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":155584,"kind":"person","name":"DOMAIN PARTERS VII L P","position":1,"cik":"0001374150","reported_name":"DOMAIN PARTERS VII L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-27T17:32:26.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":1648359,"price":1.82,"value":3000013.38,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"As managing members of One Palmer Square Associates VII, LLC, which is also the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below may also be deemed to indirectly beneficially own 49,908 shares of Common Stock held by DP VII Associates, L.P."}],"balance_after":5634329,"source":{"system":"sec-edgar","filing":"0000904454-18-000526","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000526/edgar.xml","form_type":"4"}},{"id":3833140,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"price":0,"reported_value":11048,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"reported_value","element":"transactionTotalValue","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"exercise_price":4.59,"underlying":"Common Stock","underlying_shares":2505},"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833139,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D-1 Preferred Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":27328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":638},"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833138,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":47460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1109},"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833137,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":40268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":941},"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833136,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":22161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":518},"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833135,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":50532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1180},"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833134,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":true,"shares":2505,"price":4.59,"value":11497.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $11,048. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":6891,"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833133,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-27T17:20:40.000Z","date":"2018-08-23","kind":"exercise","acquired":true,"shares":4386,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":4386,"source":{"system":"sec-edgar","filing":"0000904454-18-000524","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000524/edgar.xml","form_type":"4"}},{"id":3833125,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Stock and Warrants to Purchase Common Stock were issued and sold as units at a purchase price of $6.125 per unit.  Each unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock.  The units will separate, and the underlying Common Stock and Warrants will begin trading separately, no later than 30 days following the date of the IPO prospectus, at which time the Warrants will become exercisable for a period of five years."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Common Stock and Warrants to Purchase Common Stock were issued and sold as units at a purchase price of $6.125 per unit.  Each unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock.  The units will separate, and the underlying Common Stock and Warrants will begin trading separately, no later than 30 days following the date of the IPO prospectus, at which time the Warrants will become exercisable for a period of five years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Stock and Warrants to Purchase Common Stock were issued and sold as units at a purchase price of $6.125 per unit.  Each unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock.  The units will separate, and the underlying Common Stock and Warrants will begin trading separately, no later than 30 days following the date of the IPO prospectus, at which time the Warrants will become exercisable for a period of five years."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":15000,"derivative":{"exercise_price":6.125,"exercise_date":"2018-09-20","expiration_date":"2023-09-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833124,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"price":0,"reported_value":1488952,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"reported_value","element":"transactionTotalValue","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"exercise_price":4.59,"underlying":"Common Stock","underlying_shares":337694},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833123,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D-1 Preferred Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":3682919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":86050},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833122,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":6396105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":149441},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833121,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":5426808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":126794},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833120,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":2986762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":69784},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833119,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":false,"shares":6810098,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":159115},"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833118,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":15000,"price":6.125,"value":91875.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Stock and Warrants to Purchase Common Stock were issued and sold as units at a purchase price of $6.125 per unit.  Each unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock.  The units will separate, and the underlying Common Stock and Warrants will begin trading separately, no later than 30 days following the date of the IPO prospectus, at which time the Warrants will become exercisable for a period of five years."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":943878,"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833117,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":true,"shares":337694,"price":4.59,"value":1550015.46,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $1,488,952. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the \"Conversion Amount\") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 75% of the IPO price per share of $6.125 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":929878,"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3833116,"issuer":{"id":7831,"kind":"organization","name":"Bionano Genomics, Inc.","symbol":"BNGO"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-27T17:03:03.000Z","date":"2018-08-23","kind":"exercise","acquired":true,"shares":591184,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The Preferred Stock had no expiration date"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Partner Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":591184,"source":{"system":"sec-edgar","filing":"0000904454-18-000522","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445418000522/edgar.xml","form_type":"4"}},{"id":3882970,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T21:06:07.000Z","date":"2018-06-22","kind":"other","acquired":true,"shares":3846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."}],"balance_after":6963,"source":{"system":"sec-edgar","filing":"0000904454-18-000441","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000441/edgar.xml","form_type":"4"}},{"id":3882969,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T21:06:07.000Z","date":"2018-06-22","kind":"other","acquired":false,"shares":21471,"ownership":{"direct":false,"nature":"By Domain Associates, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a managing member of Domain Associates, LLC, the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by Domain Associates, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Associates, LLC, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-18-000441","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000441/edgar.xml","form_type":"4"}},{"id":3909046,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T16:20:50.000Z","date":"2018-05-31","kind":"other","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."}],"balance_after":36431,"source":{"system":"sec-edgar","filing":"0000904454-18-000397","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445418000397/edgar.xml","form_type":"4"}},{"id":3909045,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-04T16:20:50.000Z","date":"2018-05-31","kind":"other","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Associates, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares by Domain Associates, LLC to its members, a former member and an employee."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a Managing Member of Domain Associates, LLC and a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity.  The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-18-000397","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445418000397/edgar.xml","form_type":"4"}},{"id":3916965,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-25T20:11:25.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the one year anniversary of the date of grant or the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors at such time."}],"balance_after":10100,"derivative":{"exercise_price":38.32,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0000904454-18-000386","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000386/edgar.xml","form_type":"4"}},{"id":4063624,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-13T16:32:48.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on the date of the grant and as to an additional 2.08% at the end of each monthly period thereafter."}],"balance_after":30000,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000904454-18-000160","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000090445418000160/edgar.xml","form_type":"4"}},{"id":4088106,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase  Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"exercise","acquired":false,"shares":1193,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of DP VII Associates, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by DP VII Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"derivative":{"exercise_price":6.99,"exercise_date":"2013-07-01","expiration_date":"2018-02-12","underlying":"Common Stock","underlying_shares":1193},"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088105,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"exercise","acquired":false,"shares":70042,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Partners VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"derivative":{"exercise_price":6.99,"exercise_date":"2013-07-01","expiration_date":"2018-02-12","underlying":"Common Stock","underlying_shares":70042},"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088104,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-26","kind":"other","acquired":true,"shares":645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."}],"balance_after":3177,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088103,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-26","kind":"other","acquired":false,"shares":8500,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VII, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As a managing member of One Palmer Square Associates VII, LLC, the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by One Palmer Square Associates VII, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by One Palmer Square Associates VII, LLC, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088102,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-25","kind":"sale","acquired":false,"shares":11674,"price":71.79,"value":838076.46,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.29 to $72.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of DP VII Associates, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by DP VII Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":15329,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088101,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"tax_withholding","acquired":false,"shares":117,"price":71.82,"value":8402.94,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of DP VII Associates, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by DP VII Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":27003,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088100,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"exercise","acquired":true,"shares":1193,"price":6.99,"value":8339.07,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of DP VII Associates, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by DP VII Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":27120,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088099,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"tax_withholding","acquired":false,"shares":6814,"price":71.82,"value":489381.48,"ownership":{"direct":false,"nature":"By Domain Partners VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":1101080,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088098,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"exercise","acquired":true,"shares":70042,"price":6.99,"value":489593.58,"ownership":{"direct":false,"nature":"By Domain Partners VII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":1107894,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088097,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"other","acquired":true,"shares":8500,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VII, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 8,500 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 8,500 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As a managing member of One Palmer Square Associates VII, LLC, the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by One Palmer Square Associates VII, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by One Palmer Square Associates VII, LLC, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4088096,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T22:24:47.000Z","date":"2018-01-24","kind":"other","acquired":false,"shares":850000,"ownership":{"direct":false,"nature":"By Domain Partners VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 8,500 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 8,500 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P., the Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":1037852,"source":{"system":"sec-edgar","filing":"0000904454-18-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445418000051/edgar.xml","form_type":"4"}},{"id":4090963,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-24T16:09:52.000Z","date":"2018-01-22","kind":"other","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Associates, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"An award of 4,500 Restricted Stock Units was made to the Reporting Person in January 2017, which vested on January 17, 2018. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."},{"field":"shares","element":"transactionShares","label":"F1","text":"An award of 4,500 Restricted Stock Units was made to the Reporting Person in January 2017, which vested on January 17, 2018. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of Domain Associates, LLC and a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":46450,"source":{"system":"sec-edgar","filing":"0000904454-18-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445418000049/edgar.xml","form_type":"4"}},{"id":4090962,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-24T16:09:52.000Z","date":"2018-01-22","kind":"other","acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"An award of 4,500 Restricted Stock Units was made to the Reporting Person in January 2017, which vested on January 17, 2018. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."},{"field":"shares","element":"transactionShares","label":"F1","text":"An award of 4,500 Restricted Stock Units was made to the Reporting Person in January 2017, which vested on January 17, 2018. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."}],"balance_after":3900,"source":{"system":"sec-edgar","filing":"0000904454-18-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445418000049/edgar.xml","form_type":"4"}},{"id":4125374,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Redeemable Convertible Preferred Stock","published_at":"2017-12-20T16:51:02.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Redeemable Convertible Preferred Stock was immediately convertible upon its purchase on 04/11/2017, subject to certain conditions.  The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Redeemable Convertible Preferred Stock was immediately convertible upon its purchase on 04/11/2017, subject to certain conditions.  The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\" Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, and subject to certain conditions, into a number of shares of Common Stock determined by dividing the Accrued Value by the conversion price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"exercise_price":3.19,"underlying":"Common Stock","underlying_shares":12444},"source":{"system":"sec-edgar","filing":"0000904454-17-000741","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000741/edgar.xml","form_type":"4"}},{"id":4125373,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T16:51:02.000Z","date":"2017-12-18","kind":"grant","acquired":true,"shares":282,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person received an additional 282 shares of Common Stock from the Issuer, representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that the Reporting Person would have been entitled to receive up to and including March 31, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":25730,"source":{"system":"sec-edgar","filing":"0000904454-17-000741","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000741/edgar.xml","form_type":"4"}},{"id":4125372,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T16:51:02.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":12444,"price":3.19,"value":39696.36,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":25448,"source":{"system":"sec-edgar","filing":"0000904454-17-000741","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000741/edgar.xml","form_type":"4"}},{"id":4125371,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Redeemable Convertible Preferred Stock","published_at":"2017-12-20T16:48:32.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":49632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Redeemable Convertible Preferred Stock was immediately convertible upon its purchase on 04/11/2017, subject to certain conditions. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Redeemable Convertible Preferred Stock was immediately convertible upon its purchase on 04/11/2017, subject to certain conditions. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the \"Stated Value\") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the \"Accrued Value.\" Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, and subject to certain conditions, into a number of shares of Common Stock determined by dividing the Accrued Value by the conversion price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"exercise_price":3.19,"underlying":"Common Stock","underlying_shares":1678432},"source":{"system":"sec-edgar","filing":"0000904454-17-000739","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000739/edgar.xml","form_type":"4"}},{"id":4125370,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T16:48:32.000Z","date":"2017-12-18","kind":"grant","acquired":true,"shares":37890,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Person received an additional 37,890 shares of Common Stock from the Issuer, representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that the Reporting Person would have been entitled to receive up to and including March 31, 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":3469029,"source":{"system":"sec-edgar","filing":"0000904454-17-000739","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000739/edgar.xml","form_type":"4"}},{"id":4125369,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-20T16:48:32.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":1678432,"price":3.19,"value":5354198.08,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":3431139,"source":{"system":"sec-edgar","filing":"0000904454-17-000739","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000739/edgar.xml","form_type":"4"}},{"id":4133794,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":164155,"kind":"organization","name":"DOMAIN ASSOCIATES","position":1,"cik":"0001020733","reported_name":"DOMAIN ASSOCIATES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30494,"kind":"person","name":"Kamdar Kim P.","position":7,"cik":"0001535065","reported_name":"Kamdar Kim P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T16:58:46.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":47963,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000727","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000727/edgar.xml","form_type":"4"}},{"id":4133793,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":171195,"kind":"organization","name":"DP VI Associates, L.P.","position":1,"cik":"0001298034","reported_name":"DP VI Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T16:52:56.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":15731,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000725","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000725/edgar.xml","form_type":"4"}},{"id":4133792,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":171194,"kind":"organization","name":"Domain Partners VI, L.P.","position":1,"cik":"0001298033","reported_name":"Domain Partners VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-12-13T16:42:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":20150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the effective time of the Merger, each warrant that was outstanding and unexercised immediately prior to the effective time of the Merger, with an exercise price less than $1.52, was cancelled and converted into the right of the holder of such warrant to receive, for each share of Common Stock underlying such warrant, (i) an amount in cash equal to the excess, if any, of $1.52 over the applicable exercise price for such share, and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the effective time of the Merger, each warrant that was outstanding and unexercised immediately prior to the effective time of the Merger, with an exercise price less than $1.52, was cancelled and converted into the right of the holder of such warrant to receive, for each share of Common Stock underlying such warrant, (i) an amount in cash equal to the excess, if any, of $1.52 over the applicable exercise price for such share, and (ii) one CVR."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2013-07-15","expiration_date":"2019-10-01","underlying":"Common Stock","underlying_shares":20150},"source":{"system":"sec-edgar","filing":"0000904454-17-000722","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000722/edgar.xml","form_type":"4"}},{"id":4133791,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":171194,"kind":"organization","name":"Domain Partners VI, L.P.","position":1,"cik":"0001298033","reported_name":"Domain Partners VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-12-13T16:42:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":20150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the effective time of the Merger, each warrant that was outstanding and unexercised immediately prior to the effective time of the Merger, with an exercise price less than $1.52, was cancelled and converted into the right of the holder of such warrant to receive, for each share of Common Stock underlying such warrant, (i) an amount in cash equal to the excess, if any, of $1.52 over the applicable exercise price for such share, and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the effective time of the Merger, each warrant that was outstanding and unexercised immediately prior to the effective time of the Merger, with an exercise price less than $1.52, was cancelled and converted into the right of the holder of such warrant to receive, for each share of Common Stock underlying such warrant, (i) an amount in cash equal to the excess, if any, of $1.52 over the applicable exercise price for such share, and (ii) one CVR."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"derivative":{"exercise_price":0.67,"exercise_date":"2013-07-15","expiration_date":"2019-03-30","underlying":"Common Stock","underlying_shares":20150},"source":{"system":"sec-edgar","filing":"0000904454-17-000722","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000722/edgar.xml","form_type":"4"}},{"id":4133790,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":171194,"kind":"organization","name":"Domain Partners VI, L.P.","position":1,"cik":"0001298033","reported_name":"Domain Partners VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T16:42:31.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":1857036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VI, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000722","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000722/edgar.xml","form_type":"4"}},{"id":4133789,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":157687,"kind":"organization","name":"DP VIII Associates, L.P.","position":1,"cik":"0001465143","reported_name":"DP VIII Associates, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T16:38:43.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":7333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000720","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000720/edgar.xml","form_type":"4"}},{"id":4133788,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":157686,"kind":"organization","name":"Domain Partners VIII, L.P.","position":1,"cik":"0001465144","reported_name":"Domain Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138386,"kind":"person","name":"BLAIR JAMES C","position":2,"cik":"0001024000","reported_name":"BLAIR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153843,"kind":"person","name":"DOVEY BRIAN H","position":3,"cik":"0001207786","reported_name":"DOVEY BRIAN H","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148535,"kind":"person","name":"TREU JESSE I","position":4,"cik":"0001013425","reported_name":"TREU JESSE I","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":5,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120873,"kind":"person","name":"Halak Brian K","position":6,"cik":"0001354718","reported_name":"Halak Brian K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-13T16:32:14.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":988285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between the Issuer, MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into the Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares Common Stock of the Issuer outstanding immediately prior to the effective time of the Merger were canceled and converted automatically into the right to receive (i) $1.52 per share in cash, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt, entered into on December 7, 2017, to receive one or more payments in cash currently estimated to be up to $2.58 per share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VIII, LLC, the sole general partner of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000718","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1013425/000090445417000718/edgar.xml","form_type":"4"}},{"id":4137867,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T21:14:29.000Z","date":"2017-12-08","kind":"other","acquired":true,"shares":2472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."}],"balance_after":2472,"source":{"system":"sec-edgar","filing":"0000904454-17-000710","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445417000710/edgar.xml","form_type":"4"}},{"id":4137866,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T21:14:29.000Z","date":"2017-12-08","kind":"other","acquired":false,"shares":32560,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VII, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Distribution of shares in kind by One Palmer Square Associates VII, LLC to its members."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As a managing member of One Palmer Square Associates VII, LLC, the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by One Palmer Square Associates VII, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by One Palmer Square Associates VII, LLC, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000904454-17-000710","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445417000710/edgar.xml","form_type":"4"}},{"id":4137865,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T21:14:29.000Z","date":"2017-12-06","kind":"sale","acquired":false,"shares":9326,"price":53.85,"value":502205.1,"ownership":{"direct":false,"nature":"By DP VII Associates, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.61 to $54.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of DP VII Associates, L.P., the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by DP VII Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":25927,"source":{"system":"sec-edgar","filing":"0000904454-17-000710","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445417000710/edgar.xml","form_type":"4"}},{"id":4137864,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T21:14:29.000Z","date":"2017-12-06","kind":"other","acquired":true,"shares":3291,"ownership":{"direct":false,"nature":"By One Palmer Square Associates VII, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 3,291 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 3,291 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As a managing member of One Palmer Square Associates VII, LLC, the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by One Palmer Square Associates VII, LLC.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by One Palmer Square Associates VII, LLC, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":32560,"source":{"system":"sec-edgar","filing":"0000904454-17-000710","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445417000710/edgar.xml","form_type":"4"}},{"id":4137863,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-08T21:14:29.000Z","date":"2017-12-06","kind":"other","acquired":false,"shares":329083,"ownership":{"direct":false,"nature":"By Domain Partners VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 3,291 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Distribution of shares in kind by Domain Partners VII, L.P. to its partners, including 3,291 shares to One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As a managing member of One Palmer Square Associates VII, LLC, the sole general partner of Domain Partners VII, L.P., the Reporting Person may be deemed to indirectly beneficially own the shares of Common Stock held by Domain Partners VII, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":1887852,"source":{"system":"sec-edgar","filing":"0000904454-17-000710","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000090445417000710/edgar.xml","form_type":"4"}},{"id":4137766,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-08T16:19:54.000Z","date":"2017-12-06","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 12 equal monthly installments commencing on 1/01/2018."}],"balance_after":35000,"derivative":{"exercise_price":6.19,"expiration_date":"2027-12-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000904454-17-000712","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445417000712/edgar.xml","form_type":"4"}},{"id":4212673,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-11T17:25:53.000Z","date":"2017-09-11","kind":"other","acquired":true,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Domain Associates, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"An award of 3,300 Restricted Stock Units was made to the Reporting Person in August 2016, which vested in on August 3, 2017. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."},{"field":"shares","element":"transactionShares","label":"F1","text":"An award of 3,300 Restricted Stock Units was made to the Reporting Person in August 2016, which vested in on August 3, 2017. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of Domain Associates, LLC and a managing member of One Palmer Square Associates VI, LLC, the sole general partner of Domain Partners VI, L.P. and DP VI Associates, L.P.  Pursuant to Instruction 4(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities owned by each such entity, however she disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed her pecuniary interest therein and/or that are not actually distributed to her."}],"balance_after":44200,"source":{"system":"sec-edgar","filing":"0000904454-17-000604","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445417000604/edgar.xml","form_type":"4"}},{"id":4212672,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":79004,"kind":"person","name":"VITULLO NICOLE","position":1,"cik":"0001196863","reported_name":"VITULLO NICOLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-11T17:25:53.000Z","date":"2017-09-11","kind":"other","acquired":false,"shares":1650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"An award of 3,300 Restricted Stock Units was made to the Reporting Person in August 2016, which vested in on August 3, 2017. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."},{"field":"shares","element":"transactionShares","label":"F1","text":"An award of 3,300 Restricted Stock Units was made to the Reporting Person in August 2016, which vested in on August 3, 2017. Pursuant to the limited liability company agreement of Domain Associates, LLC, 50% of the vested shares subject to this award were transferred to Domain Associates, LLC."}],"balance_after":6150,"source":{"system":"sec-edgar","filing":"0000904454-17-000604","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000090445417000604/edgar.xml","form_type":"4"}}],"next_cursor":"2017-09-11T17:25:53.000000Z,4212672"}